Background: Hemoglobin A1c (HbA1c) provides a reliable measure of glycemic control over 2-3 months in human diabetes mellitus. In dogs, presence of HbA1c has been demonstrated, but there are no validated commercial assays. Objective: The purpose of the study was to validate a commercially available automated immunoturbidimetric assay for canine HbA1c and determine an RI in a hospital population. Methods: The specificity of the assay was assessed by inducing glycosylation in vitro using isolated canine hemoglobin, repeatability by measuring canine samples 5 times in succession, long term inter-assay imprecision by measuring supplied control materials, stability using samples stored at 4°C over 5 days and À20°C over 8 weeks, linearity by mixing samples of known HbA1c in differing proportions, and the effect of anticoagulants with paired samples. An RI was determined using EDTA-anticoagulated blood samples from 60 nondiabetic hospitalized animals of various ages and breeds. Hemoglobin A1c was also measured in 10 diabetic dogs. Results: The concentration of HbA1c increased proportionally with glucose concentration in vitro. For repeat measurements, the CV was 4.08% (range 1.16-6.10%). Samples were stable for 5 days at 4°C. The assay was linear within the assessed range. Heparin-and EDTA-anticoagulated blood provided comparable results. The RI for HbA1c was 9-18.5 mmol/mol. There was no apparent effect of age or breed on HbA1c. In diabetic dogs, HbA1c ranged from 14 to 48 mmol/mol. Conclusions: The assay provides a reliable method for canine HbA1c measurement with good analytic performance.
Introduction
Glycosylated hemoglobin A1c (HbA1c) is formed when glucose binds to the n-terminal valine of the b-subunit of hemoglobin A and makes up the largest fraction of the total glycosylated hemoglobin (HbA1). 1 The total amount of HbA1c formed is dependent on erythrocyte lifespan, erythrocyte permeability to glucose, and the average blood glucose concentration throughout the erythrocyte lifespan. 1 In people it is related to the average blood glucose concentration over the preceding 2-3 months, weighted toward the most recent 2-4 weeks. 2 The concentration of fructosamine-the sum of glycosylated plasma proteins-is currently a commonly used measure of longer term diabetic stability in the dog. Fructosamine is related to the average blood glucose concentration over the previous 1-2 weeks. 3, 4 However, a number of factors other than plasma glucose concentration affect fructosamine concentration including hypoproteinemia, hyperlipidemia, and azotemia. 4 Compared to fructosamine measurements, HbA1c is less affected by pathologic conditions other than diabetes mellitus. 5 In people, HbA1c has been established as a highly specific and reliable biomarker for the long-term control of both type 1 6 and type 2 diabetes mellitus. 7 Glycosylated hemoglobin A1c is also used prognostically with increasing values corresponding to an increased risk of diabetic complications. 6 In dogs, there have been no studies looking at the relationship between fructosamine or HbA1c and outcome in diabetes mellitus.
The measurement of HbA1c in dogs has been previously described. Several methods developed for human use have been evaluated for use in canine diabetes mellitus but none have been adopted into standard clinical practice. All published studies have, however, shown that canine diabetics have higher average ratios of glycosylated hemoglobin to total hemoglobin compared to nondiabetic controls. 3, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] The first aim of this study was to determine the effect of increasing glucose concentrations on the formation of canine HbA1c as measured by an immunoturbidimetric assay, the Siemens DCA Vantage (Siemens Healthcare plc., Surrey, UK), in canine erythrocyte preparations. The second aim was to validate this method and to establish an RI from a hospital population. The final aim was to assess the effect of breed predisposition and age on canine HbA1c within the reference population.
Materials and Methods

Animals and samples
All specimens were collected from dogs referred to the Small Animal Hospital, University of Glasgow. Ethics approval for this study was obtained from the School of Veterinary Medicine Ethics and Welfare committee, University of Glasgow. Surplus EDTA-and heparinanticoagulated blood from samples that had been taken for diagnostic purposes by jugular venipuncture were used for the study with individual consent obtained from each client for the use of these residual samples.
Hospital population
Screening for eligibility for the RI population occurred between June and August 2015. The inclusion criteria were a CBC (Cell-Dyn hematology analyzer; Abbott Laboratories, North Chicago, IL, USA) with manual WBC differential counts, and biochemistry analyses including a plasma glucose concentration of 3-7 mmol/L (54-126 mg/dL) measured by the hexokinase G-6-PDH method in a fluoride oxalate-anticoagulated sample within 8 h of collection using an Olympus AU640 biochemistry analyzer (Olympus Corporation, Tokyo, Japan). As part of the biochemistry analyses, cholesterol (by combined cholesterol esterase/oxidase method) and triglycerides (by combined lipolysis/glycerol kinase/glycerol phosphate oxidase method) were also measured on the Olympus AU640. Exclusion criteria were a diagnosis of diabetes mellitus or other endocrine disorders. Grossly hemolyzed and lipemic samples were excluded. Animals with a HGB concentration < 12 g/dL were also excluded from the RI population as anemia has been shown to have an effect on HbA1c concentrations in previous canine studies. 13, 16 Animals with diseases unrelated to carbohydrate metabolism were not excluded. Information was collected on the animal's age, breed, sex, comorbidities, current medication, blood glucose, and HGB concentration, as well as any abnormalities found in hematology and biochemistry profiles. To ensure the inclusion of a wide range of dogs in the RI population, dogs were prospectively recruited into 4 similarly sized subgroups based on age and diabetic predisposition; young (≤ 5 years old) nonpredisposed, older (> 5 years old) nonpredisposed, young predisposed, and older predisposed. The diabetic predisposition was based on previous studies (Table S1 ).
Diabetic population
Surplus heparin-and EDTA-anticoagulated blood samples collected for monitoring purposes were available for 10 diabetic dogs receiving insulin therapy and whose owners had consented to this use. Diagnosis had been confirmed before sample collection on the basis of consistent clinical signs including polyuria, polydipsia, and weight loss, and concurrent hyperglycemia and glucosuria. Information was collected on age, breed, sex, comorbidities, medications, blood glucose, and HGB concentration, and any hematologic and biochemical abnormalities, as well as any serum fructosamine measurements performed using the nitrotetrazolium blue reduction method on an Olympus AU640 biochemistry analyzer with the ABX Horiba reagent kit (Horiba UK Ltd -Medical, Northampton, UK) as part of routine monitoring.
Analysis of HbA1c
Samples were analyzed on a DCA Vantage using HbA1c reagent cartridges (Hemoglobin A1c reagent kit; Siemens DCA Systems, Surrey, UK) which contain all reagents in a single disposable cartridge that the sample is drawn into by capillary action, effectively eliminating carryover. The Siemens DCA Vantage uses murine anti-human HbA1c monoclonal antibodies specific to the last few amino acids on the N-terminal of the b-chain. 19 Although canine and human hemoglobin A are only 80% homologous, the first 5 residues of the N-terminal of the b-chain are identical. 16 Hemoglobin A1c in the sample competitively inhibits the agglutination of latex particles coated with murine anti-HbA1c antibodies resulting in decreased light absorbance at 531 nm. Concurrently total hemoglobin is measured following the oxidation to methemoglobin, complexed with thiocyanate to form a colored compound which is measured spectrophotometrically at 531 nm. Hemoglobin A1c is expressed as a proportion of total HGB in mmol/mol within a 6-min reaction time.
The samples were analyzed according to the manufacturer's instructions using 1 lL of EDTA-anticoagulated blood. Before each batch run, and when changing cartridge batch numbers, a quality control was performed with one normal (range 24.6-48.6 mmol/ mol) and one high (range 70-116.4 mmol/mol) commercial human control reagent (Siemens DCA systems).
Incubation of canine hemoglobin with glucose
The EDTA-anticoagulated blood from 5 nondiabetic dogs with no hematologic abnormalities was pooled. This sample was washed 3 times with phosphate-buffered saline by centrifuging at 1439g using a Beckman Coulter Allegra X-12R (Beckman Coulter, High Wycombe, UK) for 10 min. The washed erythrocytes were hemolyzed using a modified osmotic shock procedure 20 , then centrifuged at 2249g for 15 min to sediment the cell debris. The hemolysate was divided into 5 aliquots of 600 lL, and incubated with serial glucose concentrations of 0, 50, 100, 200, and 400 mmol/L (equivalent to 900, 1800, 3600, and 7200 mg/dL), stored at room temperature, and measured at days 0, 7, 11, and 17 after preparation. A separate pool of intact erythrocytes was washed in the same manner and half the sample was hemolyzed for determination of interference by hemolysis (see below). Both hemolysates and intact erythrocytes were divided into 500 lL aliquots and incubated at 4°C in the same glucose concentrations as the room temperature hemolysates. Samples were measured at 0, 4, 7, and 14 days after preparation.
Repeatability and storage
Samples were collected as described previously from both diabetic and nondiabetic animals to represent a large range of glucose concentrations. To evaluate the repeatability, the HbA1c in each sample (n = 4) was measured 5 times in succession. To evaluate the interassay variability over the course of the study, the results from the commercially available quality control materials were used.
Storage stability was evaluated using 3 EDTAanticoagulated samples kept at 4°C. Samples were measured at baseline and then for 4 consecutive days, with the measurements at each time point compared to baseline. Stability of canine HbA1c at À20°C was assessed by freezing 5 samples, and measuring these after 4 and 8 weeks and comparing the results to baseline.
Linearity
Samples from 2 dogs were measured and used, covering the tentative RI and the diabetic range after mixing them in serial proportions (25:75, 50:50, and 75:25) to create 3 new intermediate expected values. The measured HbA1c concentrations were then compared to the calculated expected HbA1c concentrations. 21 The linearity was determined for both EDTA-and heparinanticoagulated samples to assess both linearity of the assay and the effect of different anticoagulants to the measured HbA1c.
Interference
An initial investigation into the effect of lipemia on the assay was performed by measuring HbA1c in EDTAanticoagulated samples from 7 dogs with known triglyceride (0.68-25.58 mmol/L) and cholesterol (4.9-11.7 mmol/L) concentrations. After assessing the baseline HbA1c, the samples were centrifuged (Beckman Coulter Allegra X-12R) at 2073g and 6°C for 12 min, and the plasma was completely removed and replaced by an equal volume of 0.9% NaCl. The packed red cells were resuspended by mixing well and the HbA1c was measured in the delipidated specimen.
To assess the effect of complete hemolysis on HbA1c measurements, the baseline results from the hemolyzed preparations used in the 4°C glucose incubation experiments (described earlier) were compared to the results from the intact erythrocyte preparations (which were from the same pooled sample but had not undergone hemolysis).
Statistical methods
Statistical analysis was carried out with SPSS v22 (IBM) or Microsoft Excel 2010 for Windows with
Reference Value Advisor Add-In. 22 Statistical significance was set at P < .05 for all analyses.
For the glucose incubation, regression lines of measured HbA1c over time were fitted for each glucose concentration and compared against the blank (0 mmol/L glucose). The change in HbA1c from baseline was compared to glucose concentration for each time point using a linear regression and Pearson's correlation.
To evaluate linearity, a least squares regression analysis was performed on expected against observed measurements. The difference between EDTA and heparin anticoagulant was evaluated by calculating the mean difference and performing a least squares regression analysis.
The RI for the nondiabetic hospital population was determined using the nonparametric method with bootstrapping to arrive at the 90% CI for the whole population. 22 Both Tukey and Dixon-Reed tests were used to identify potential outliers. The RI comprises the central 95%, with 90% CI around the lower and upper limits. All factors assessed including HbA1c, age, breed predisposition, sex, blood glucose, and HGB concentration were summarized descriptively. Linear regression and correlations were performed to look at the relationship between HbA1c and glucose concentration, age, and HGB concentration. A regression model of HbA1c was fitted with age, HGB concentration, sex, breed predisposition, and glucose concentration as cofactors.
A Kruskal-Wallis ANOVA was used to assess the overall difference in HbA1c between the prespecified RI subgroups. Subgroup analysis was performed within the reference population by comparing the median HbA1c in each subgroup to that of the median HbA1c of the other subgroups combined using a Mann-Whitney U test.
For the diabetic population, all factors assessed were summarized descriptively and compared to the RI population. Normally distributed factors were compared using an independent sample t-test and nonnormally distributed factors were compared using a Mann-Whitney U test.
Results
The in vitro HbA1c formation at room temperature using canine hemolysates from 5 pooled canine blood samples increased with time and glucose concentration (Figure 1) , and the measured HbA1c concentrations were significantly different from each other (P < .001). In addition, the change in HbA1c from baseline against glucose concentration resulted in a linear relationship on day 7 (Pearson's correlation .968, R 2 linear .937, P = .007), day 11 (R 2 .941, P = .006), and day 17 (R 2 .941, P = .006). The increase in HbA1c over time was initially linear for all glucose concentrations, but between days 11 and 17, the rate of change started to decrease. Further points were not measured. The aliquots kept at 4°C did not show any significant deviations from baseline after 14 days.
The intra-assay precision was good with a mean CV of 4.08% (range 1.16-6.10%, 5 repeats) (Table 1) , with a maximum difference of 2 mmol/mol between the highest and lowest measurement within any sample. One measurement of 57 mmol/mol was excluded from the analysis of the diabetic samples due to operator error.
The inter-assay imprecision for the normal concentration quality control material (stabilized human hemoglobin) supplied by the manufacturer over the course of the study was also acceptable with a mean CV of 2.97%. The inter-assay imprecision with the high HbA1c commercial control had a higher CV of 8.81%. Bias was seen with an overestimation of the mean relative to the stated value (mean 93.5 mmol/ mol) ( Table 1) .
The variation for stored canine samples over 5 days was low with a mean CV of 2.12% (Table 1) . The maximum absolute change from baseline at any time point was 1 mmol/mol with a mean change from baseline after 5 days of À0.3 mmol/mol. After freezing for 4 weeks, the variation was also low compared to baseline with a maximum absolute change of 1 mmol/ mol. After 8 weeks of freezing, 4 samples showed a small change from baseline with the 5 th showing a decrease of 7 mmol/mol (À14%) from baseline. In the linearity study, the regression analysis of the heparin-and EDTA-anticoagulated blood samples gave a linear relationship for both (R 2 = .982 and .957, respectively) ( Figure 2 ). For EDTA samples, the y intercept was À2.23 mmol/mol (95% CI À4.539 to 0.077 mmol/mol) and the slope was 1.031 (95% CI 0.951-1.111). For the heparin samples, the y intercept was À1.846 mmol/mol (95% CI À5.5 to 1.8 mmol/ mol) and the slope 1.046 (95% CI 0.918-1.174). For both lines, the y intercept was not significantly different from 0, the slope was not different from 1, and the lines were not significantly different from each other Figure 1 . Change in hemoglobin A1c (HbA1c) in canine pooled blood hemolysates incubated with increasing concentrations of glucose at room temperature. ♦ 400 mM glucose, ▼ 200 mM glucose, ▲ 100 mM glucose, ■ 50 mM glucose, • 0 mM glucose.
(P = .92). The mean difference between the heparin and EDTA samples was À0.8 mmol/mol.
The interference by lipemia was tested on 4 samples from diabetic dogs, 2 from nondiabetic dogs with gross hyperlipemia, and one control from the RI population. The initial HbA1c concentrations ranged from 11 to 34 mmol/mol with a trend for increasing interference from lipids with increasing triglyceride and cholesterol concentrations ( Table 2 ). The largest difference was 6 mmol/mol (60% change from baseline for sample 5 and a 20.7% change for sample 7).
The HbA1c values obtained from the hemolyzed pooled sample were higher (mean 22 mmol/mol, range 20-24 mmol/mol) than in the nonhemolyzed preparation (mean 17.75 mmol/mol, range 17-19 mmol/mol), with no overlap between the 2 samples.
The RI population (n = 60) included 9 predisposed and 18 nonpredisposed breeds. The most common predisposed breeds were Border Collies (n = 9), Bichon Fris es (n = 3), Cavalier King Charles Spaniels (n = 3), and Yorkshire terriers (n = 2). The most common nonpredisposed breeds were Labradors (n = 6), mixedbreeds (n = 5), German Shepherds (n = 5), Golden Retrievers (n = 4), and Cocker Spaniels (n = 4). No outliers were excluded. The distribution of the reference values was not normal (P = .03), showing evidence of a binomial distribution (Figure 3 ). Using the nonparametric method (n > 40), an RI for HbA1c of 9-18.5 mmol/mol was determined with the 90% CI of the lower limit being 9-10.5 mmol/mol and of the upper limit being 18-19 mmol/mol. The median was 14 mmol/mol HbA1c (mean 14.3 mmol/mol, SD 2.5) with a total range of 9-19 mmol/mol for the RI population (Table 3) .
There was a weak positive correlation between HbA1c and plasma glucose concentration within the RI population (Spearman's r .332, R 2 = .089). The correlations between age and HbA1c, and between HGB and HbA1c were not significant within the RI population. Within the regression model, the overall adjusted R 2 was low (.146), and the only significant factor was glucose concentration (P = .02) with an increase in HbA1c of 1.259 mmol/mol for every 1 mmol/L increase in plasma glucose concentration. The regression model also showed that age, HGB concentration, sex (including neuter status) and breed, had no statistically significant effect on HbA1c (P = .09, .23, and .68, respectively).
Differences in age, sex, and breed predisposition were observed between the groups in the RI population (Table 3) , but only the old nonpredisposed group Bias was calculated by the following formula: = (mean reported À mean measured)/mean reported*100. had a higher HbA1c (mean 15.28 mmol/mol) when compared to the rest of the RI (mean 13.88 mmol/mol, P = .045). There were no significant differences in HbA1c across the subgroups using a Kruskal-Wallis ANOVA. There were also no significant differences when partitioning by age (P = .442) or breed predisposition (P = .213) (Figure 3 ). The group of diabetic dogs (n = 10) was significantly older (P = .005) and included a higher proportion of dogs of predisposed breeds (7/10) (P = .047) compared to the RI population. As expected, the diabetic group had significantly higher glucose concentrations (mean 19.56 mmol/L vs 4.9 mmol/L, P < .001) ( Table 3 ). The mean HbA1c concentration was also significantly higher (36.5 mmol/mol vs 14.3 mmol/mol, P < .001) (Figure 4 ). There were no differences in HGB concentrations (P = .454) and sex distribution (P = .442) between the diabetic group and the entire RI population. Within the diabetic group, there was no significant correlation between HbA1c and glucose concentration (n = 9, P = .618) or fructosamine (n = 6, P = .827).
Discussion
Using pooled hemolyzed erythrocytes from nondiabetic dogs, it was demonstrated that in vitro incubation with increasing glucose concentrations increased the proportion of HbA1c. From the known kinetics of the reaction 1,2 and work using human erythrocyte preparations 23 , this expected increase suggests that the DCA Vantage is measuring a stable canine HbA1c fraction, and that canine HbA1c can be used for the long-term glycemic control of a canine patient. Using human erythrocytes it was previously shown that HbA1c increases with increasing glucose concentrations at 4°C. 23 However, this was not replicated in our experiments, with HbA1c not increasing significantly from baseline after 14 days. The previous study used agar gel electrophoresis for detecting HbA1c, which does not differentiate between stable and labile fractions of HbA1c. However, the formation of labile HbA1c occurs 11.9 times faster than formation of stable HbA1c. 2 The only previous study using canine erythrocyte preparations also determined labile HbA1c, after an incubation of 6 hours with one high glucose concentration. 18 Due to the differences, the results from these studies are not directly comparable with the present study. Intact erythrocytes were not used for the room temperature glucose incubation as they are prone to an extensive yet variable hemolysis. 24 Using hemolysates controlled this variable, but made the model less representative of in vivo conditions. We were, however, able to show that canine HbA1c increased in a dose-dependent manner with increasing glucose concentrations at room temperature. Despite unphysiologically high glucose concentrations, the reaction was slow. The results from this in vitro incubation are also consistent with previous findings that persistent hyperglycemia over 2 weeks is needed in order to see increases in HbA1c in dogs in vivo. 13 Important components of a method validation study are imprecision and accuracy. 25 Imprecision in the DCA Vantage was low with a CV of 2.97% for the normal commercial quality control. This is comparable to CVs obtained by several independent studies validating the DCA Vantage for use with human specimens with a CV < 3.1%. 26, 27 Slightly higher CVs of 4.08% (range 1.16-6.10%) were obtained during assessment of inter-assay variation using canine samples, mainly due to the low samples showing proportionally much more variation with an overall range of 1 mmol/mol compared to samples with a higher value. The overall imprecision is likely to be acceptable for veterinary use when compared to the allowable imprecision in other similar laboratory variables such as glucose concentration. 28 A much higher inter-assay variation (8.81%) was obtained from the high control. It is known that the DCA Vantage exhibits increased variance at readings above 64 mmol/mol. 26 However, as the number of diabetic animals included in the study was small (with a maximum HbA1c of 48 mmol/mol), the diagnostic impact is unclear. Bias in the DCA Vantage could not be assessed for canine HbA1c measurements due to the absence of a canine reference method and the lack of availability of previously validated methods. Furthermore, canine HbA1c cannot be measured using high-performance liquid chromatography which is a reference method for human HbA1c. 3, 11, 18 With the human reference material, the high control showed considerable bias compared to the reported mean of the material (À11.98%), but this was marginal in the normal control (À0.81%).
The effect of storage at 4°C was minimal with a mean change from baseline of À0.33 mmol/mol after 5 days. Different samples were used for the repeatability and storage assessments so variation cannot be compared directly, but the total variance from the storage assessment (CV 2.12%) was comparable to the inter-assay variation.
The linearity study provided an indirect assessment of bias. The regression analysis confirmed that the line obtained experimentally was not significantly different from y = x and thus, there was no internal bias against expected values. The results obtained in our study are consistent with human data from independent studies. 19, 26 As the high HbA1c used in assessing linearity was markedly lower than the highest reading obtained from any animal in this study (40 mmol/mol vs 48 mmol/mol), and with the known bias seen with the high control material, there is potential for an unknown bias in the upper expected working ranges of the assay which suggests that we have not fully established the reportable range of this assay for canine HbA1c. However, validation of this assay for human samples has established a reportable range of < 143 mmol/mol. 19 No significant difference was found between measurements obtained from blood anticoagulated with EDTA or heparin for analysis. The mean difference of À0.8 mmol/mol and lack of significant difference between the regression lines suggest that these anticoagulants can be used interchangeably in the measurement of canine HbA1c.
In these preliminary investigations, hemolysis and hyperlipemia appear to interfere with the HbA1c measurement obtained by the DCA Vantage. The preliminary investigations were designed to test whether there was interference when using patient samples within the concentration range of interferent expected with clinical use, to determine where further investigation was warranted. 29 The manufacturers report a bias of À1.81% for human samples with triglyceride concentrations of 15.2 mmol/L for HbA1c measurements in the 42-48 mmol/mol range, but no data on the magnitude of interference beyond this are available. As dogs may have triglyceride concentrations
, it was important to determine whether there may be an effect of hyperlipemia on the HbA1c as measured by the DCA Vantage. Canine samples with a total lipid concentration of ≥ 25 mmol/L showed increase from baseline in measured HbA1c concentration after lipid removal that were larger than the inherent imprecision within the method. This indicates that measured HbA1c may be artificially reduced in samples with gross hyperlipemia and this should be investigated further using established guidelines. 21 Similarly, hemolysis of a pooled sample significantly increased the HbA1c concentration compared to baseline. This was surprising as the DCA Vantage includes an internal hemolysis step before analysis. As so far only 100% hemolysis has been investigated, further studies are needed to determine the maximum acceptable sample hemolysis. The third standard interferent, bilirubin, was not studied due to lack of adequate samples.
The RI was 9-18.5 mmol/mol for canine HbA1c in a hospital population of 60 dogs, which is lower compared to the human RI of 20-42 mmol/mol. This is partially explainable by the lower glucose permeability of canine erythrocytes compared to human erythrocytes.
1 When comparing our RI to those in previously evaluated methods for canine HbA1c 16, 17 , it was significantly lower. Notably, one of the previous studies 35 determined health based on the absence of clinical signs and did not specifically exclude anemic dogs.
Anemic dogs were excluded in our study due to the evidence of effects on canine HbA1c independent of glucose concentration. 13, 16, 31 A hospital population of dogs may not mirror the real healthy canine population, despite evidence that most pathologic processes do not affect HbA1c. 13 A previous study did not show any differences between the RI obtained from a hospital sample compared to healthy animals, but their healthy population consisted of 18 juvenile colony Beagles. 3 Currently, the collection of samples from healthy animals for research purposes is precluded based on animal welfare legislation. 32 The RI is, however, relevant to dogs presented to a small animal hospital, therefore using an RI from a hospital population seems appropriate. The group size is another potential limitation in this study in that it reduced the power of the study to detect small differences between subgroups. While a previous study with a larger sample size showed a normal distribution 11 , the distribution of reference values of HbA1c in our study was not normal. The reason for binomial distribution is not clear. The group size was large enough, however, to establish an RI in line with American Society of Veterinary Clinical Pathology (ASVCP) recommendations 33 with good confidence in the range as shown by the tight 90% CIs.
A special point of interest in establishment of RIs were reference population subgroups. For instance, the HbA1c concentration was significantly higher in the old nonpredisposed group when compared to the remaining 3 groups combined, while a Kruskal-Wallis ANOVA identified no significant differences between the groups, including an absence of significant differences between young and aged groups, which is consistent with previous studies. 3, 14 Likewise, no difference was determined for HbA1c concentrations between predisposed and other breeds, which has not been reported before. However, it is acknowledged that, as we only looked at predisposed compared to nonpredisposed breeds, our categorization may have reduced the ability to detect a true difference in HbA1c in specific breeds or in the small subgroup of nonpredisposed breeds that might be considered "protected" against diabetes mellitus.
Our finding will need to be confirmed with additional studies involving larger numbers of dogs and more breeds with varying incidence of diabetes mellitus. Predisposed breeds are not likely to have a higher HbA1c as the clinical course of canine diabetes mellitus is comparable to human type 1 disease. 34, 35 However, little is known about breed differences in erythrocyte permeability, and as at least one breed-associated difference has been identified 36 , it follows that there may be breed-specific HbA1c concentrations.
In order for canine HbA1c to be established as an effective biomarker for long-term diabetic control, an independent objective assessment of diabetic control needs to be developed. This would require a gold standard method of long-term diabetic control to investigate the diagnostic power of HbA1c and fructosamine as biomarkers.
